A phase II second-line study of pemetrexed (pem) in combination with bevacizumab (bev) in patients with advanced non-small cell lung cancer (NSCLC): An NCCTG and SWOG study.

Adjei, A. A. ,  Mandrekar, S. J. ,  Dy, G. K. ,  Molina, J. R. ... -    -  J. Clin. Oncol.   -  2008    

Abstract -  Primary -  Primary -  Respiratory -  NCCTG-N0426